Document is current

Article History

Accepted: 1 October 2024

First Online: 24 October 2024

Declarations

:

: Harinala Groyer and Denis San were employed by Boehringer Ingelheim France at the time of manuscript submission. Romain SUPIOT, Jean TARDU, Nicolas VIRELY, and Marine SIVIGNON were employed by Putnam at the time of manuscript submission. Pierre Lévy reports serving on a consultancy or paid advisory board for Bayer, Boehringer Ingelheim, Newcard. Anastasia Ustyugova is employed by Boehringer Ingelheim International GmbH, Ingelheim, Germany. Ziad Massy reports having received grants for CKD-REIN and other research projects from Amgen, Baxter, Fresenius Medical Care, GlaxoSmithKline, Merck Sharp & Dohme-Chibret, Sanofi- Genzyme, Lilly, Otsuka, AstraZeneca, Vifor, and the French government, as well as fees and grants to charities from AstraZeneca, Boehringer Ingelheim, and GlaxoSmithKline. The sponsors had no role in the design, execution, interpretation, or writing of the present study.

: Not applicable.

: Not applicable.

: Not applicable.

: No other data or material are available than the ones published in this article.

: No code or information from the cost-effectiveness model is available.

: The authors meet criteria for authorship as recommended by the International Committee of Medical Journal Editors (ICMJE). Harinala Groyer managed the project on the Boehringer Ingelheim side and proofread the manuscript. Romain Supiot managed the project on the Putnam side and wrote the manuscript. Jean Tardu, Nicolas Virely, Marine Sivignon, Denis San, and Anastasia Ustyugova contributed to the analysis and proofread the manuscript. Pierre Lévy was consulted as an economic expert and proofread the manuscript. Ziad Massy was consulted as a clinical expert to validate assumptions and key inputs of the model and proofread the manuscript.

: The study was supported and funded by Boehringer Ingelheim.